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Abstract
Background:  Insulin resistance is often associated with increased levels of intracellular
triglycerides, diacylglycerol and decreased fat β-oxidation. It was unknown if this relationship was
present in patients with acute insulin resistance induced by trauma.
Methods: A double blind placebo controlled trial was conducted in 18 children with severe burn
injury. Metabolic studies to assess whole body palmitate oxidation and insulin sensitivity, muscle
biopsies for mitochondrial palmitate oxidation, diacylglycerol, fatty acyl Co-A and fatty acyl
carnitine concentrations, and magnetic resonance spectroscopy for muscle and liver triglycerides
were compared before and after two weeks of placebo or PPAR-α agonist treatment.
Results: Insulin sensitivity and basal whole body palmitate oxidation as measured with an isotope
tracer increased significantly (P = 0.003 and P = 0.004, respectively) after PPAR-α agonist treatment
compared to placebo. Mitochondrial palmitate oxidation rates in muscle samples increased
significantly after PPAR-α treatment (P = 0.002). However, the concentrations of muscle
triglyceride, diacylglycerol, fatty acyl CoA, fatty acyl carnitine, and liver triglycerides did not change
with either treatment. PKC-θ activation during hyper-insulinemia decreased significantly following
PPAR-α treatment.
Conclusion: PPAR-α agonist treatment increases palmitate oxidation and decreases PKC activity
along with reduced insulin sensitivity in acute trauma, However, a direct link between these
responses cannot be attributed to alterations in intracellular lipid concentrations.
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Background
Significant alterations in both glucose and fat metabolism
occur following burn trauma. Hyperglycemia, due to
increased hepatic gluconeogenesis and peripheral insulin
resistance, is common [1]. Free fatty acid (FFA) cycling is
increased up to three fold, and triglyceride (TAG) deposi-
tion in the liver is common [2]. Studies in burned animals
indicate that mitochondrial number and oxidative capac-
ity are severely reduced following burn, but how these
changes relate to in vivo fatty acid oxidation is unclear [3].
Further, the relation between fat metabolism and insulin
sensitivity is not well understood in the severely burned
population.
Decreased β-oxidation of FFA's and increased circulating
concentrations of plasma FFA's are both likely related to
insulin resistance. Offspring of type 2 diabetics who
appear otherwise healthy have increased intracellular
muscle and liver fat and decreased mitochondrial
number, size, and fatty acid oxidation rates [4,5]. It has
been theorized that a decrease in mitochondrial function,
and thus β-oxidation, causes intracellular TAG to accumu-
late, thereby contributing to the development of insulin
resistance [6]. The accumulation of tissue TAG may not
only be due to a decrease in the oxidation rate of fatty
acids, but also to an increase in fatty acid delivery via
plasma TAG and FFA. It is further proposed that intra-cel-
lular TAG per se may not cause insulin resistance, but
instead may be associated with increases in TAG metabo-
lites such as diacylglycerol (DAG) and long chain fatty
acyl CoA [6]. Both DAG and long chain fatty acyl CoA
have been shown to disrupt the insulin signaling pathway
at the level of the insulin receptor signalling-1 protein
(IRS-1), preventing translocation of glucose transporter to
the cell surface membrane, and thus insulin stimulated
glucose uptake [6]. This response has been proposed to be
mediated by activation of protein kinase C-θ (PKC-θ) and
protein kinase C-β (PKC-β) [6].
Peroxisome proliferator activating receptors (PPAR) are
nuclear receptors that, when stimulated by endogenous
lipids, activate specific genes involved in fat metabolism.
Of interest is the apparent ability of PPAR-α agonists to
increase fat oxidation and improve insulin sensitivity. Sig-
nificant decreases in fasting plasma glucose, insulin and
TAG, with a concomitant decrease in muscle and liver
TAG have been reported in lipoatrophic mice, mice given
high fat diets and diabetic Zucker rats after treatment with
PPAR-α agonists [7,8]. PPAR-α agonists also decrease
intracellular fatty acyl CoA and malonyl CoA, and
increase fatty acid oxidation in rodents [9,10]. PPAR-α
agonist treatment in human myocytes increased β-oxida-
tion of oleate and decreased oleate incorporation into
TAG [11]. Despite the encouraging results in animal and
in vitro studies, results of treatment in young and middle
aged humans with PPAR-α agonists have not been as well
defined [12-14]. Thus, in certain models the PPAR-α ago-
nists affect fat metabolism by increasing mitochondrial
oxidative capacity, yet the role in humans is not well
established.
We have recently demonstrated that PPAR-α agonist treat-
ment improves both peripheral and hepatic glucose sensi-
tivity and improves the response of the insulin signaling
cascade in muscle to insulin in burns [15] but, the effect
of PPAR-α agonism on fat metabolism has not been
examined. Further, thermal injury in pediatric patients
provides unique model to investigate acute onset insulin
resistance, since the injuries are similar and quantifiable,
and the patients rarely have pre-existing medical condi-
tions. For this reason, we investigated if the PPAR-α ago-
nist fenofibrate could increase palmitate oxidation and
decrease intracellular lipids, presumably through increas-
ing mitochondrial fatty acid oxidation in pediatric burn
trauma patients.
Research design and methods
This was a prospective, randomized, double-blind pla-
cebo controlled clinical trial. The protocol was approved
by the IRB at the University of Texas Medical Branch. A
legal guardian provided permission for participation of
the child. Assent was obtained in children aged 7–17
when medically possible.
Children aged 4–17 and > 20 kg with > 40% total body
surface area burns that would require skin grafting, who
arrived at our hospital within 96 hours of injury were eli-
gible. Children with major electrical burns, renal or
hepatic failure, iodine allergies, severe sepsis or previous
cardiac arrest were excluded.
Two 8 hour isotopic tracer studies were conducted ~2
weeks apart (Figure 1). The studies were performed ~4
days after the child's first and third excision and skin auto-
grafting operations. This timing avoided acute surgery-
induced metabolic changes, yet made use of the existing
arterial and venous access. The two week treatment inter-
val was chosen so as to guarantee similar clinical condi-
tions in all patients, since many patients with burns 40–
60% may be discharged from intensive care after recovery
from their third surgery.
Children were treated between the studies daily with
either the PPAR-α agonist fenofibrate (Tricor©) or placebo,
as pre-determined by a randomization schedule. Five mg/
kg of fenofibrate was ground in 1–2 cc of 200 proof ethyl
alcohol and suspended in drug suspension agent with fla-
voring. The placebo consisted of the suspension and fla-
voring agents. Treating physicians and nurses were
blinded to drug allocations.Nutrition & Metabolism 2007, 4:9 http://www.nutritionandmetabolism.com/content/4/1/9
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Overall study design and tracer design Figure 1
Overall study design and tracer design. A) Overall randomization B) Tracer infusion protocol. A four hour basal period 
was followed a four hour hyperinsulinemic-euglycemic clamp. Glucose isotopes were infused for the duration of the study, and 
palmitate for the last two hours of each period.
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Each study was preceded by a 4 hour fast with IV fluids of
only saline, and 8 hours without blood or albumin trans-
fusions. Background samples were taken from a venous
catheter prior to a 4 hour basal period, followed by a 4
hour hyperinsulinemic-euglycemic clamp. During the
clamp, insulin was infused at a rate of 1.5 mU/kg/min
into a central vein and 20% Dextrose was simultaneously
infused to maintain a plasma glucose concentration
between 80–90 mg/dL. An infusion of U-13C palmitate
was started at a rate of 0.08 µmol/min/kg after a 150
µmol/kg NaH13CO3 prime two hours after the start of
each period, and 80 minutes were allowed to reach steady
state before four sets of arterial and venous blood samples
and breath samples were taken 10 min apart. A V-max 29
metabolic cart (Sensormedics, Yorba Linda, CA) was used
during the sampling period to measure the volume of CO2
expired. The same primed infusion of U-13C palmitate was
again started 2 hours after the start of the clamp with an
identical sampling schedule. Liver and soleus TG were
assessed by magnetic resonance spectroscopy (MRS) as
described previously [16].
Medical care was determined by faculty surgeons, fellows
and residents according to clinical protocols that have
been previously described [17]. Patients were fed with
Vivonex T.E.N. © (Novartis, Minneapolis, Minnesota -82%
carbohydrate, 15% protein, 3% fat) at 1.4 times their
measured resting energy expenditure. The resting meta-
bolic rate was determined once a week in the early morn-
ing at 30°C with a V-max 29 metabolic cart
(Sensormedics, Yorba Linda, CA). The patients received
nutritional supplements including a multi-vitamin, folic
acid, zinc, and vitamin C.
Plasma FFA's were isolated as described previously for
analysis of concentration and enrichment [18]. The iso-
lated FFA solid was transferred into FAME and reconsti-
tuted in heptane for GC and MS. Enrichment was
measured with an HP-6890 GC/Agilent 5973 Mass Spec-
trometer (Wilmington, DE) for the ions of [M+0]+,
[M+15]+ and [M+16]+ at m/z 270, 285 and 286, corre-
sponding to the molecular ions of palmitate and its iso-
topic tracers. Concentrations were measured on a HP-
5890 GC-FID with 3392A integrator or a HP-6890 GC-
FID (Agilent technologies, Palo Alto, CA), using heptade-
canoic acid as an internal standard.
Blood CO2 samples were collected in 15 ml vacutainer
tubes containing 85% phosphoric acid and breath CO2
samples were collected in plain 15 ml vacutainer tubes.
Samples were analyzed with IRMS (VG ISOGAS, Cheshire,
England) and a standard curve prepared from the phos-
phoric acid and 45 CO2 standard (Bayer, East Walpole,
MA) was used to calculate the blood CO2 concentration.
Plasma glucose concentration was measured on an YSI
2300 Stat glucose/lactate analyzer (YSI, Inc. Yellow
Springs, OH). The isotopic enrichment of the penta-ace-
tate derivative of plasma glucose was determined by GC/
MS as described previously [19]. Serum insulin concentra-
tions were measured using radioactive immuno assay
(Diagnostic Laboratories, Los Angeles, CA).
Liver fat (LFAT) and muscle triglycerides (IMCL) were
measured using magnetic resonance spectroscopy as
described previously [16], except that the settings of the
scans were altered to decrease the amount of time in the
machine for the patients. For the liver scans, 128 scans
were performed, rather than 256, and a repetition time
1188 ms was used rather than 2000 ms. For the IMCL
scans, the repetition time was also decreased to 1188 ms.
Muscle DAG concentrations were measured as previously
described [20]. Fatty acyl-carnitine and CoA concentra-
tions were measured in muscle tissue as previously
described [21,22].
Mitochondrial enzyme activity of β-hydroxyacetyl buter-
ate (β-HAD) was measured from homogenates of vastus
lateralis biopsies in a sucrose/EDTA/Tris buffer as previ-
ously described [23]. Maximal mitochondrial coupled
and uncoupled oxidation of palmitate in the presence of
excess carnitine were measured in permeabilized skinned
muscle fibers from fresh muscle tissue as previously
described [24]. Following these measurements, the sam-
ples were weighed, and the citrate synthase activity and
protein contents were measured [25,26].
The concentration of membrane bound, or activated PKC-
θ and PKC-β were measured from frozen muscle samples
using Western-blot separation and antibody probing
methods [27].
Calculations
The rate of endogenous palmitate release by adipocytes
(appearance into plasma) was calculated by measuring
the dilution of the infused tracer by unlabeled palmitate.
The calculation was:
where arterial enrichment is expressed as tracer/tracee
ratio and palmitate tracer infusion rate as µmol/kg/min.
To calculate the rate of whole body fat oxidation, the fol-
lowing equation was used:
Rate of appearance
tracer infusion
arterial enrichment
=
Palmitate Oxidation
Enrichment CO Volume CO
Precursor Enr
=
× 22
i ich Acetate Corr M M ×× + × + + × (% % ) 16 16 15 15Nutrition & Metabolism 2007, 4:9 http://www.nutritionandmetabolism.com/content/4/1/9
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The precursor enrichment measurement was made prior
to the infusion of the tracer and the acetate correction fac-
tor used for these calculations was 0.90, as determined by
studies in a similar patient population of pediatric burns
using 1,2 C13-Acetate [28]. %M+16 and %M+15 are the
percentages of M+16 and M+15 in the precursor pool.
Glucose infusion rate in mg/kg/min was calculated by
measuring the amount of 20% dextrose infused to main-
tain plasma glucose between 80–90 mg/dL and corrected
for the actual concentration of dextrose (16–19%).
Statistics
All data are presented as the mean ± standard error of the
mean. Results within each group were compared between
pre and post-treatment with a two-tail paired students t-
test. The basal and clamp periods were also compared in
this manner. The change from the pre-to post treatment
was compared between the two treatment groups with a
one tailed unpaired t-test. All statistics were preformed
with Sigma Stat software package, version 2.03.
Results
9 children in each group completed the study. The mean
age was 8 ± 1 years in the placebo (PLA) and 6 ± 1 years in
fenofibrate (FEN). The groups were similar in terms of
gender and race distribution, with the majority of patients
Hispanic males. The burn size was approximately 65% in
both groups, and the percent third degree burn was simi-
lar between groups, and above 40%. Detailed clinical data
have been presented previously [15], but there were no
significant hepatic or renal abnormalities, and both
groups were similar at baseline. Plasma lipids were
unchanged with treatment in either group (Table 1).
Plasma cortisol, TNF-α and IL1 and Il-6 were unchanged
by either treatment [15].
We have previously shown that fenofibrate treatment sig-
nificantly increases insulin stimulated glucose uptake by
59 ± 11% compared to 16 ± 19% in placebo, and that the
children have insulin sensitivity that is 50 to 75% lower
than expected [15]. Further, fenofibrate may increase
hepatic suppression of glucose release in response to insu-
lin [15]. The rate of whole body fat oxidation pretreat-
ment was similar between the groups (Table 2). During
hyper-insulinemia, fat oxidation was suppressed to
approximately 40% of basal values. Post-treatment, the
basal rate of palmitate oxidation in PLA was unchanged,
whereas there was a significant (P = 0.004) increase in
FEN. During hyper-insulinemia post-treatment, oxidation
decreased in a similar proportion as pre-treatment. The
percent of palmitate taken up by tissues and subsequently
oxidized was the same at pre-treatment in both groups
during basal and clamp periods. After treatment the per-
centage of palmitate oxidized during the basal states
increased substantially in FEN, but not PLA (P =
0.04)(Table 2).
The systemic release of FFA in the body was quantified as
the appearance of palmitate and was similar in both
groups pre-treatment. Palmitate appearance was not sig-
nificantly suppressed during hyper-insulinemia (Table 2).
Post-treatment the release of palmitate in both groups was
similar to the respective pre-treatment values, and again
the suppression of FFA appearance during hyper-insuline-
mia was not significant.
Pre-treatment, PKC-β activity tended to increase during
the clamp compared to the basal state in both treatment
groups (Table 2). After treatment- the response of PKC-β
activation was the same. PKC-θ activity did not respond to
insulin pre-treatment. In PLA after treatment, the basal
activity of PKC-θ trended to increase and there was no dif-
ference between the clamp and basal states after treat-
ment. The basal state of PKC-θ in FEN post-treatment was
similar to that seen in the other groups. However, follow-
ing the insulin infusion, the level of PKC-θ was signifi-
cantly decreased compared to the pre-treatment clamp
activity (P = 0.004).
Liver fat was assessed by MRS in 7 of 9 children in each
group. There was no change in LFAT or soleus IMCL after
treatment in either group (Table 3) Total (16:0, 18:0, 18:1
and 18:2) DAG and total long chain fatty acyl CoA from
Table 1: Plasma Lipids
PLA FEN
Measurement Pre Post Pre Post
Cholesterol 92 ± 8 100 ± 5 73 ± 8 92 ± 6
Triglycerides 163 ± 32 116 ± 9 121 ± 8 168 ± 16
HDL 14 ± 8 20 ± 2 8 ± 1 14 ± 2
L D L 4 6  ±  85 6  ±  44 3  ±  84 7  ±  6
V L D L 3 3  ±  62 3  ±  22 4  ±  23 6  ±  4
Plasma lipids Measured before and after placebo or fenofibrate treatment. There were no significant changes with treatment in any of the plasma 
lipid measured in either group.Nutrition & Metabolism 2007, 4:9 http://www.nutritionandmetabolism.com/content/4/1/9
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muscle biopsy samples were also unaltered with treat-
ment (Table 3) In DAG, the predominate species was 18:0
(32–46% of total), whereas 18:1 was the predominate
species in both fatty Acyl CoA (46–50% of total) and Car-
nitine (40–43% of total).
The mitochondrial state 3 oxidative respiration of palmi-
tate, which is coupled with ADP use, was increased fol-
lowing treatment in FEN (P = 0.03) and decreased
following treatment in PLA (P = 0.02) (Table 4). The state
4 uncoupled oxidative rate did not change with either
treatment, although there was trend for increase in PLA,
and thus the ratio of state 3 to state 4 oxidation, or respi-
ratory control ratio, increased significantly in FEN, com-
pared to PLA (Table 4). The increased respiratory control
ratio, reflective of an increased proportion of coupled oxi-
dation, could not be explained by a change in the activity
level of β-HAD, a key mitochondrial enzyme in FFA oxi-
dation, which did not significantly change from pre to
post treatment in either the PLA or the FEN groups (Table
3).
Discussion
Whole body palmitate oxidation was increased signifi-
cantly following PPAR-α agonist treatment in the basal
state when compared to placebo, as was the percentage of
palmitate oxidized. The improvement at the whole body
level was reflected by increased muscle mitochondrial
Table 3: 
PLA FEN
Measurement Pre Post Pre Post
LFAT (% LFAT/control) 26 ± 9 27 ± 9 24 ± 7 30 ± 9
IMCL (% IMCL/control) 27 ± 8 18 ± 7 30 ± 16 22 ± 9
Total DAG (pmol/mg) 482 ± 92 380 ± 59 341 ± 102 357 ± 75
Total Long Chain fatty acyl CoA (pmol/mg) 6.0 ± 1.1 5.0 ± 0.8 5.4 ± 0.5 6.4 ± 1.1
Total Long chain fatty Acyl carnitine (pmol/mg) 55 ± 18 62 ± 18 56 ± 13 58 ± 19
Percent of CoA/Carnitine 10 ± 6 8 ± 4 9 ± 4 10 ± 5
Basal levels of intracellular triglyceride percentages for the liver and soleus muscle are shown, and did not change with treatment in either group. 
Basal concentrations of total long chain species (16:0, 16:1, 18:0, 18:1 and 18:2) of DAG, fatty acyl CoA and fatty acyl carnitine also did not change 
with either treatment.
Table 2: Palmitate kinetics and Protein Kinase-C activation
PLA FEN
Measurement Pre Post Pre Post
Palmitate oxidation
Basal 0.85 ± 0.19 1.03 ± 0.12 0.99 ± 0.13 1.40 ± 0.13*
Clamp 0.32 ± 0.05† 0.44 ± 0.04†* 0.35 ± 0.05† 0.74 ± 0.13†*
Percent uptake 
oxidized
B a s a l 2 8  ±  32 8  ±  32 4  ±  2 3 0  ±  2 *
C l a m p 2 7  ±  32 8  ±  12 7  ±  33 7  ±  5
Palmitate Release
Basal 2.96 ± 0.5 3.66 ± 0.3 4.06 ± 0.4 4.7 ± 0.3
Clamp 1.20 ± 0.2† 1.94 ± 0.2† 1.15 ± 0.2† 2.04 ± 0.3†
PKC-β
Basal 0.35 ± 0.10 0.30 ± 0.11 0.25 ± 0.04 0.70 ± 0.25
Clamp 1.12 ± 0.60 1.64 ± 0.70 1.99 ± 0.58 1.64 ± 0.46
PKC-θ
Basal 1.38 ± 0.27 1.15 ± 0.36 0.87 ± 0.28 1.26 ± 0.38
Clamp 0.98 ± 0.17 1.15 ± 0.48 0.87 ± 0.31 0.33 ± 0.11*
The rate of palmitate oxidation is shown in (µmol/kg/min), percent uptake oxidation and whole body palmitate release (µmol/kg/min). * indicates a 
change from pre to post treatment, and † represents a change from basal to clamp. Of interest was a significant increases in the rate of palmitate 
oxidation in the basal (P = 0.004) and clamp (P = 0.03) states following fenofibrate treatment, and the percent uptake oxidized (P = 0.04) Protein 
Kinase-C β membrane translocation is shown in relative units, representing activation in both the basal and the clamp hyper-insulinemic state 
following fenofibrate treatment. Protein Kinase-C θ membrane translocation, representing activation representing activation in both the basal and 
the clamp hyper-insulinemic state following fenofibrate treatment. * The activation of PKC-θ decreased significantly during hyper-insulinemia 
following fenofibrate treatment (P = 0.004).Nutrition & Metabolism 2007, 4:9 http://www.nutritionandmetabolism.com/content/4/1/9
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capacity for palmate oxidation, but these changes were
not due to an increase in β-HAD, and based on the CoA to
carnitine ratio, were not likely due to change in fatty acid
entry into the mitochondria. These changes in fat oxida-
tion were accompanied by decreased PKC-θ activation, yet
the basal concentrations of proposed upstream signaling
molecules such as TAG, DAG or fatty acyl CoA were not
significantly changed with fenofibrate treatment. Further,
plasma lipid concentrations were unaffected by fenofi-
brate treatment.
While this finding of PPAR-α induced increase in palmi-
tate oxidation is unique in humans, similar findings have
been found in animal studies [29]. Further, a very potent
PPAR-α agonist was shown to increase palmitate oxida-
tion in human hepatic and muscle cells in a dose depend-
ant manner [30]. No prior studies have measured the
effect of PPAR-α agonist treatment in burn patients.
The LFAT measurements in these burned children were
similar to those that we have previously found in elderly
subjects with insulin resistance [16]. While we have not
measured LFAT in healthy children, it can be assumed that
this would be low and similar to concentrations in
healthy young adults. If this is true, measured LFAT was
increased 3 to 4 fold in children at week 1 post-burn, and
remained elevated regardless of fenofibrate treatment. It is
possible the LFAT was elevated as soon as the first study,
as LFAT in pigs doubled four days post-burn [31]. Fenofi-
brate may not have decreased LFAT because of the short
duration of treatment. Animal studies that demonstrated
decreased hepatic TAG's after PPAR-α agonist treatment
generally have used much larger doses for longer periods
of time [7-10]. Furthermore, the endogenous expression
of the PPAR-α receptor is much higher in animals than in
humans [32]. Thus, while we were unable to detect an
effect of PPAR-α of LFAT in this population, perhaps
increased doses would affect a metabolic change.
Levels of IMCL were similar to those seen in elderly adults
and did not change in either treatment group [16]. Fur-
ther, the lack of change in the presence of increased palmi-
tate oxidation indicates that increases in IMCL levels may
not be due only to decreased oxidation of intracellular lip-
ids. IMCL levels may be increased secondary to adipocyte
dysfunction and this may account for the relationship
noted in patients with increased adiposity, insulin resist-
ance and increased IMCL [33].
Some studies have found close associations between intra-
cellular lipids such as TAG, DAG and fatty acyl-CoA and
insulin sensitivity [6]. However, we did not find these
associations in burned children. Basal concentrations of
DAG, TAG, fatty acyl-CoA and fatty acyl carnitine did not
decrease significantly as insulin sensitivity increased fol-
lowing PPAR-α treatment in the fenofibrate treatment
group. Whereas there may be a Type II error with the var-
iability of the data prior to treatment, the lack of change
within each treatment groups, especially the fenofibrate
group indicates that there was not a change in DAG con-
centrations with treatment. Similar results were reported
in rats fed a high fat diet that had over expression of
hepatic malonyl CoA dehydrogenase [34]. Malonyl CoA
dehydrogenase breaks down malonyl CoA and presuma-
bly increases β-oxidation of fats. Muscle, fat and whole
body insulin sensitivity improved in these animals but
IMCL did not change, and there was a trend for increased
fatty acyl CoA production. Furthermore, rats fed a high fat
diet and treated with Wy-14643, a potent PPAR-α agonist,
demonstrated an increase in long chain fatty acyl-CoA's
and insulin mediated glucose uptake, and decreased intra-
muscular TAG [35]. A similar study found that chronic
WY-14643 administration in rats did not lower palmitoyl
CoA [36]. Four weeks of treatment in overweight, diabetic
ob/ob rats, with WY-16643, had no effect on palmitoyl
CoA in muscle, and increased oleoyl CoA more than ten-
fold in skeletal muscle [37]. These conflicting results indi-
cate that the association between intracellular lipids and
insulin sensitivity is perhaps not as clear as previously
thought. The fact that the fatty acid distribution in DAG
differs from that in other intracellular lipids, which sug-
gests that there is not a straightforward precursor-product
Table 4: Mitochondrial oxidation and enzyme levels
PLA FEN
Measurement Pre Post Pre Post
State 3 oxidation (µmol O2/mg CS/min) 0.87 ± 0.05 0.73 ± 0.07* 0.80 ± 0.10 1.17 ± 0.12*
State 4 oxidation (µmol O2/mg CS/min) 0.58 ± 0.04 0.73 ± 0.13 0.60 ± 0.06 0.60 ± 0.07
Ratio of State3/State4 1.51 ± 0.11 1.30 ± 0.31 1.40 ± 0.17 2.01 ± 0.16*
β-HAD (µmol substrate/g wet tissue/min) 5.0 ± 0.9 4.3 ± 1.4 4.0 ± 0.8 4.5 ± 0.8
State 3 respiration of palmitate in (µmol 02/CS mg protein/min) improved significantly (P = 0.03) after treatment in FEN, whereas there was a 
significant decrease seen in PLA (P = 0.02) State 4 oxidation of palmitate in (µmol 02/CS mg protein/min) did not change with either treatment. The 
ratio of state 3 to state 4 palmitate oxidation improved significantly (P = 0.02) following fenofibrate treatment. The concentration of β-HAD did not 
change in either group with treatment. * indicates significant change from Pre to post treatment.Nutrition & Metabolism 2007, 4:9 http://www.nutritionandmetabolism.com/content/4/1/9
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relation as previously suggested [33] further complicates
the potential link between altered intracellular lipids,
insulin signaling and insulin sensitivity.
It is possible that the increase in mitochondrial oxidation
was due to changes in the respiratory chain, rather than at
other regulatory sites within fatty acid metabolism. We
have previously documented that PPAR-α agonism
increases pyruvate oxidation, and with similar results
found with a palmitate substrate, the site of increased
metabolism would need to be regulatory site common to
both, i.e. either the TCA cycle or the respiratory chain [15].
Further, if fatty acyl CoA is rapidly broken down within
the mitochondria, then the ratio of fatty acyl CoA to fatty
acyl carnitine can be used as a rough estimate of carnitine
palmitate transferase-1 (CPT-1) activity. We found that
there was substantially more fatty acyl carnitine than CoA,
perhaps indicating that CPT-1 was not inhibited. Further,
since the mitochondrial oxidation of palmitate and pyru-
vate are similar, and pyruvate metabolism is not affected
by CPT-1, it is unlikely that this is the site of PPAR-α activ-
ity.
PKC-β and PKC-θ are both found in skeletal muscle and
the activities vary in animals and humans, and thus we
studied both [38]. The levels of PKC-β increased during
insulin stimulation in all of the groups, yet increased the
most in the PLA groups after treatment. Insulin did not
affect PKC-θ pre-treatment, or in the PLA post-treatment,
yet there was a significant decrease in PKC-θ in FEN after
treatment. No studies to date have looked at the effect of
PPAR-α agonists on PKC activity. PKC has been associated
with insulin resistance in many settings. PKCs are thought
to be inhibitory to glucose transporter translocation by
causing serine phosphorylation of the insulin receptor
and IRS-1 [6]. In animals overfed with either fat or glu-
cose, increased levels of activated PKC and insulin resist-
ance have been found [39,40]. Increased levels of
activated PKC have also been found in diabetic patients
[41]. Thus, the reduction in PKC activity may be associ-
ated with improved insulin sensitivity. However, the
increase in PKC with insulin resistance is typically associ-
ated with increased concentrations of DAG, and we did
not observe this relationship between PKC and basal con-
centrations of DAG.
Conclusion
Fat metabolism in burn patients is altered by PPAR-α ago-
nist treatment. Whole body and mitochondrial oxidation
of palmitate were increased following treatment, com-
pared to placebo. Further, PKC activity changed with
fenofibrate treatment. However, fenofibrate did not lower
the basal concentrations of either liver fat, muscle TAG,
DAG, fatty acyl carnitine or fatty acyl-CoA. It may be that
the mechanism of insulin resistance post-trauma differs
from that seen in diabetes.
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